TDC
ACOR

Thompson Davis & Co’s Acorda Therapeutics ACOR Stock Holding History

Thompson Davis & Co’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-2
Closed -$10K – 875
2014
Q1 		$10K Sell
2
-6
-75% -$24.3K 0.02% 491
2013
Q4 		$29K Buy
+8
New +$31.2K 0.04% 301

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Thompson Davis & Co's ACOR Position: Q2 2014 in Review

Thompson Davis & Co sold out of Acorda Therapeutics (ACOR) in Q2 2014, closing a stake of 2 shares — an estimated $10K sold.

Thompson Davis & Co first reported a position in ACOR in Q4 2013 and held it in 2 quarters. The position peaked at $29K in Q4 2013. 162 funds tracked by Wall St. Rank hold ACOR as of Q2 2014.

  • Thompson Davis & Co reported no remaining Acorda Therapeutics position as of Q2 2014 after selling out during the quarter.
  • Thompson Davis & Co sold 2 Acorda Therapeutics shares in Q2 2014, an estimated $10K.
  • Thompson Davis & Co first reported a position in Acorda Therapeutics in Q4 2013 and held it in 2 quarters.
  • Thompson Davis & Co's Acorda Therapeutics position peaked at $29K in Q4 2013.
  • 162 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2014.

Based on Thompson Davis & Co's 13F filing for Q2 2014, filed 12 Aug 2014.